Education
About Us
Working with TipRanks
Follow Us
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
IDYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.45 - $44.42
Previous CloseN/A
Volume96.34K
Average Volume (3M)1.47M
Market Cap
$1.67B
Enterprise Value$1.59B
Total Cash (Recent Filing)-$13.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 13, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.30
Shares Outstanding87,537,390
10 Day Avg. Volume1,754,710
30 Day Avg. Volume1,468,689
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)229.97
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit226.79
Enterprise Value/Ebitda-4.88
Forecast
1Y Price Target
$51.75Price Target Upside171.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyVision improvement on-therapy prior to radiation within the plaque cohort is observed, with preliminary notes of 'clear evidence of improvement of vision on neoadjuvant therapy.'
Clinical TrialsThe total sample size for the trial has increased to 520 due to the decision to expand the pool of plaque patients, which indicates a comprehensive approach.
Regulatory AdvancementsFDA Breakthrough Therapy Designation for monotherapy darovasertib in neoadjuvant uveal melanoma may accelerate future FDA interactions and review processes.
Bears Say
Financial ConcernsIDYA has an annualized cash burn of $300 million, which may concern investors regarding long-term financial sustainability.
Investor SentimentShort interest represents 13.8% of the float, indicating a significant level of skepticism among some investors.
Regulatory ChallengesAn accelerated approval opportunity, which the company previously highlighted as a possibility, is unlikely.
---
Ownership Overview
0.89% Insiders
34.15% Mutual Funds
28.74% Other Institutional Investors
22.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IDYA FAQ
What was IDEAYA Biosciences’s price range in the past 12 months?
IDEAYA Biosciences lowest stock price was $13.45 and its highest was $44.42 in the past 12 months.
What is IDEAYA Biosciences’s market cap?
IDEAYA Biosciences’s market cap is $1.67B.
When is IDEAYA Biosciences’s upcoming earnings report date?
IDEAYA Biosciences’s upcoming earnings report date is May 13, 2025 which is in 17 days.
How were IDEAYA Biosciences’s earnings last quarter?
IDEAYA Biosciences released its earnings results on Feb 13, 2025. The company reported -$1.49 earnings per share for the quarter, missing the consensus estimate of -$0.629 by -$0.861.
Is IDEAYA Biosciences overvalued?
According to Wall Street analysts IDEAYA Biosciences’s price is currently Undervalued.
Does IDEAYA Biosciences pay dividends?
IDEAYA Biosciences does not currently pay dividends.
What is IDEAYA Biosciences’s EPS estimate?
IDEAYA Biosciences’s EPS estimate is -0.66.
How many shares outstanding does IDEAYA Biosciences have?
IDEAYA Biosciences has 87,537,390 shares outstanding.
What happened to IDEAYA Biosciences’s price movement after its last earnings report?
IDEAYA Biosciences reported an EPS of -$1.49 in its last earnings report, missing expectations of -$0.629. Following the earnings report the stock price went down -5.421%.
Which hedge fund is a major shareholder of IDEAYA Biosciences?
Currently, no hedge funds are holding shares in IDYA
---
IDEAYA Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.75 (171.37% Upside)
$51.75 (171.37% Upside)
Blogger Sentiment
Bullish
IDYA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 185.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.14%
12-Months-Change
Fundamentals
Return on Equity
-32.67%
Trailing 12-Months
Asset Growth
73.12%
Trailing 12-Months
Company Description
IDEAYA Biosciences
IDEAYA Biosciences, Inc. (IDYA) is a biotechnology company dedicated to the discovery and development of precision medicine therapies targeting cancer and other genetically defined diseases. The company operates in the field of synthetic lethality, a novel approach to cancer treatment that exploits genetic vulnerabilities in cancer cells. IDEAYA's core products include a pipeline of small molecule therapeutics focused on the areas of synthetic lethality and immuno-oncology.
---
IDYA Stock 12 Month Forecast
Average Price Target
$51.75
▲(171.37% Upside)
Technical Analysis
89bio
―
Beam Therapeutics
―
Kymera Therapeutics
―
Immunocore Holdings
―
CG Oncology, Inc.
―
Best Analysts Covering IDYA
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+30.85%
reiterated a buy rating 13 days ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +30.85% per trade.
---